
PEA is an endocannabinoid-like lipid mediator with anti-inflammatory, analgesic, antimicrobial, immunomodulatory and neuroprotective effects.

Likely reduces symptoms of retinal diseases like macular degeneration and glaucoma.

May reduce risk of [[COVID]] induced injuries.

#supplement #anti-inflammatory #glaucoma-protective #retina-protective #neuroprotective 

[[(PDF) The Use of Palmitoylethanolamide in the Treatment of Long COVID - A Real-Life Retrospective Cohort Study - 2022]]

[[(PDF) Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages - A Case-Control Study - 2022]]

[[(PDF) Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19 - A Randomized Controlled Trial - 2022]]

[[(PDF) Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19 - Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications - 2022]]

[[(PDF) Micronized, ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation - 2021]]

[[(PDF) Palmitoylethanolamide - A Natural Compound for Health Management - 2021]]

[[(PDF) Natural Products - Evidence for Neuroprotection to Be Exploited in Glaucoma - 2020]]